Back to search results

Nerivio® for Amplified Musculoskeletal Pain Syndrome (AMPS) in Children

This study is looking at how well a device called Nerivio® helps children aged 8 to 18 with Amplified Musculoskeletal Pain Syndrome (AMPS). AMPS causes ongoing, severe pain in muscles and bones. Nerivio® is a wearable device that you use on your upper arm. It works by activating certain nerves, which then sends signals to the brain. This approach has been helpful for people with migraine headaches. The study wants to see if Nerivio® can reduce pain, improve quality of life, and how satisfied children and their families are with using it. Participants will either use the Nerivio® device or continue with their usual pain care. The study aims to enroll 40 children with a confirmed AMPS diagnosis and ongoing pain.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 participants.
What's involved
Participants will commit to a four-week treatment period, using the Nerivio® device once every 48 hours or continuing their usual care.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured over a four-week intervention period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07249931

Efficacy and Safety of Nerivio for the Management of Amplified Musculoskeletal Pain Syndrome in Pediatric Patients

Not Yet Recruiting
NAAges 8–18InterventionalTreatment
Children's Health
~40 participants
Updated 2025-11-25 on ClinicalTrials.gov
What's tested:Nerivio(R) DeviceUsual Care

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment
Measured over over a four-week intervention period.

Conditions

Amplified Musculoskeletal Pain Syndrome (AMPS)

Explore related trials

Pain Amplification Syndrome

Where it's being run

1 sites across 1 states
Texas1

Who to contact

Elizabeth Wong, MSN, APRN, CPNP-PC, PMGT-BC
[email protected]
214-793-2036
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Confirmed diagnosis of AMPS by a medical provider experienced in pediatric pain management
Chronic musculoskeletal pain ≥3 months
Baseline pain intensity of ≥4 on a 0-10/10 Numeric Rating Scale (NRS)
Able to comprehend and follow instructions for the device use
Access to compatible smartphone or device to operate the Nerivio app
Commit to a four-week treatment and data collection period
Must be age 8 years - 18 years old

Exclusion

Active autoimmune disease.
Use of implantable electronic medical devices.
Neurological disorders that impair study participation as determined by the enrolling provider.
Severe Mood disorders
Recent change in pain medications or psychotropic medications (within last 4 weeks)
Currently or plan to be pregnant (Urine or blood HCG testing done upon enrollment)
Inability to comply with study procedures or use the device as directed

What this trial measures

  • Treatmentover a four-week intervention period.

    Measure change from baseline in pain scores to reported pain scores after using the Nerivio device for pediatric patients with AMPS.